Looking Both Ways For Your Small Biopharma Clients

A molecule progressing through the development lifecycle is bound to encounter obstacles in the form of shifting regulations, supply shortfalls, and limited CMC resources, all requiring flexibility and expertise. If gone unnoticed, changes in FDA regulations can cause delays in IND filing until new data requirements for testing are fulfilled. Experience with evolving regulatory landscapes is critical for a molecule advancing to market. Utilizing a robust tech transfer plan is also imperative for eliminating the loss of data or process development reports, avoiding delays and unnecessary costs.

Learn how a CDMO partner with deep technical and regulatory expertise and flexible support options is critical to advance your molecule toward commercialization with speed and reduced costs.